← Back to Search

Janus Kinase (JAK) Inhibitor

Experimental: Povorcitinib Dose A for Vitiligo

Phase 3
Recruiting
Research Sponsored by Incyte Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Agreement to discontinue all agents and procedures used to treat vitiligo from screening through the final safety follow-up visit.
Aged ≥ 18 years.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 52 and week 104
Awards & highlights

Study Summary

This trial tests a new drug to treat vitiligo, a skin disorder that causes discoloration.

Who is the study for?
This trial is for adults over 18 with nonsegmental vitiligo, which causes loss of skin color in blotches. Participants should have a certain level of skin involvement and agree to stop other vitiligo treatments during the study. They must also take precautions to prevent pregnancy or avoid fathering children.Check my eligibility
What is being tested?
The trial is testing Povorcitinib's effectiveness and safety against a placebo in treating nonsegmental vitiligo. Participants will randomly receive either the actual drug or a placebo to compare results between the two groups.See study design
What are the potential side effects?
While specific side effects are not listed here, common ones may include reactions at the medication application site, potential liver issues, headaches, nausea, or other symptoms as seen with similar medications.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I agree to stop all vitiligo treatments during the study.
Select...
I am 18 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 52 and week 104
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 52 and week 104 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Proportion of Participants Achieving a ≥ 75% Improvement From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI75)
Secondary outcome measures
Change from baseline in the Hospital Anxiety and Depression Scale (HADS) subscales
Change from baseline in the Vitiligo-Specific Quality of Life (VitiQoL)
Number of participants with Treatment-emergent Adverse Events (TEAEs)
+19 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Experimental: Povorcitinib Dose AExperimental Treatment1 Intervention
Participants will receive Povorcitinib Dose A for 52 weeks, followed by Povorcitinib Dose A for 52 weeks.
Group II: PlaceboPlacebo Group1 Intervention
Participants will receive Placebo for 52 weeks, followed by Povorcitinib Dose A for 52 weeks.

Find a Location

Who is running the clinical trial?

Incyte CorporationLead Sponsor
365 Previous Clinical Trials
54,851 Total Patients Enrolled
9 Trials studying Vitiligo
2,068 Patients Enrolled for Vitiligo
Incyte Medical MonitorStudy DirectorIncyte Corporation
23 Previous Clinical Trials
4,628 Total Patients Enrolled
1 Trials studying Vitiligo
444 Patients Enrolled for Vitiligo

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are participants being accepted for this clinical venture at the moment?

"Affirmative. The research posted on clinicaltrials.gov states that this trial, which went live on December 4th 2023, is actively recruiting participants. 444 people are needed to be enrolled from 74 different locations for the study's completion."

Answered by AI

Is Experimental: Povorcitinib Dose A deemed to be safe for human consumption?

"Our evaluation of Experimental: Povorcitinib Dose A's safety landed it a score of 3, since there is evidence to suggest efficacy and numerous accounts verifying its risk-free use."

Answered by AI

Are there multiple centers administering this clinical investigation within the US?

"Currently, 74 medical centres across the globe are enrolling patients into this trial. Locations span from Portland to Nice and New york to numerous other places. Select a nearby site in order to reduce travel demands if you choose to partake in the experiment."

Answered by AI

What is the cap on the number of participants in this investigation?

"A total of 444 eligible patients are required to complete this clinical trial. Study centres in Portland, Oregon and Nice, New york will be enrolling participants that satisfy the specified inclusion criteria."

Answered by AI

What objectives are being sought after through this research endeavor?

"This clinical trial, which will be completed in a 52-week time frame, primarily seeks to measure the proportion of participants who experience at least 50% improvement from their baseline Total Body Vitiligo Area Scoring Index (T-VASI50). Secondary outcomes include measuring the proportions of those attaining T-VASI75 and Static Investigator Global Assessment (SIGA) scores as well as tracking patient's self reports through Total Body Patient Global Impression of Change - Vitiligo (T-PaGIC V), based on a seven point scale."

Answered by AI

Who else is applying?

What site did they apply to?
Delricht Research
Other
Advanced Medical Research Pc
Dundee Dermatology
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria

Why did patients apply to this trial?

OPZETURA (ruxolitinib)cream 1.5% No test done to date. I want to be part of a life changing journey to find treatments.
PatientReceived 1 prior treatment
I'd really like to help the cause to get more treatment options out there for Vitiligo.
PatientReceived 1 prior treatment
I've had vitaligo my whole life and have never tried any treatment. I recently started to develop depigment on my face and just wanted to see after almost 40 years living with vitaligo what my options are.
PatientReceived 2+ prior treatments

What questions have other patients asked about this trial?

What is the compensation?
PatientReceived 2+ prior treatments
Recent research and studies
clinicaltrials.govStudy
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)
2023. "A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06113471.
All > Vitiligo > Spokane
~296 spots leftby May 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top